AbbVie Reports First-Quarter 2024 Financial Results
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...
Source: prnewswire.com
Page 11 - Priority Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Priority Review Today - Breaking & Trending Today
Media Update: New data presented at ATS demonstrate Sanofi's leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases
Media Update New data presented at ATS demonstrate Sanofi's leadership in advancing potential new therapies for patients with immune-mediated respiratory...
Source: marketscreener.com
FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight
The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight.
Source: highlandcountypress.com
Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
EQS-News: Heidelberg Pharma AG / Key word: Quarterly / Interim Statement Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 25.04.2024 /...
Source: marketscreener.com
Junshi Biosciences Announces NDA Acceptance in Hong Kong
SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading...
Source: globenewswire.com